Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios

Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International urology and nephrology Jg. 51; H. 12; S. 2107 - 2117
Hauptverfasser:	Cetin, Bulent, Kosar, Alim
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Dordrecht Springer Netherlands 01.12.2019 Springer Nature B.V
Schlagworte:	Aged Carcinoma, Renal Cell - therapy Clear cell-type renal cell carcinoma Clinical trials Clinical Trials as Topic Decision making Drug development Female Humans Immune checkpoint inhibitors Immunotherapy Kidney cancer Kidney Neoplasms - therapy Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Molecular Targeted Therapy Monoclonal antibodies Nephrology Patients Risk groups Targeted cancer therapy Tyrosine Urology Urology - Review Vascular endothelial growth factor Metastatic renal cell carcinoma Immunotherapy Tyrosine kinase inhibitors
ISSN:	0301-1623, 1573-2584, 1573-2584
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC. Materials and methods Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC. Results Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC. Conclusion In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work.
AbstractList	ObjectivesTreatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC.Materials and methodsBetween 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC.ResultsImmunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC.ConclusionIn renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work. Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC. Materials and methods Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC. Results Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC. Conclusion In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work. Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC. Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC. Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC. In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work. Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC.OBJECTIVESTreatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is immunotherapy, targeted therapy, or the combination of immunotherapy with targeted therapy the best for patients? Objective 2 is to study which regimens with the highest chance of cure/durable response and what is the optimal sequence in advanced RCC.Between 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC.MATERIALS AND METHODSBetween 2016 and 2018, 6 adult patients admitted to our institute with RCC were reviewed. Clinical information, treatment and outcomes were retrieved for further analysis. This applies to all risk groups as determined by the International Metastatic RCC Database Consortium criteria. We have intended to provide the reader with a comprehensive and authoritative review of the broad subject of RCC.Immunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC.RESULTSImmunotherapy-based regimens and the functioning of various growth-and survival-promoting kinases, specifically, receptor-associated tyrosine kinases have dramatically changed the treatment landscape of advanced RCC. Recent phase III trials have demonstrated a survival benefit for front-line ipilimumab plus nivolumab therapy, and immune checkpoint inhibition plus anti-vascular endothelial growth factor combination therapy in metastatic clear-cell RCC.In renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work.CONCLUSIONIn renal cell carcinoma, rapid and successful drug development has resulted in multiple treatment options, requiring careful decision making for individual patients and have emphasized how newly developed therapies work.
Author	Kosar, Alim Cetin, Bulent
Author_xml	– sequence: 1 givenname: Bulent orcidid: 0000-0001-8628-0864 surname: Cetin fullname: Cetin, Bulent email: caretta06@hotmail.com organization: Department of Internal Medicine, Division of Medical Oncology, Suleyman Demirel University, Faculty of Medicine – sequence: 2 givenname: Alim surname: Kosar fullname: Kosar, Alim organization: Department of Urology, Suleyman Demirel University, Faculty of Medicine
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31468288$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU1r3DAQhkVJaTZJ_0APRdBLL05npJUs91ZC8wGBXpqz0MrjxMGWtpJcyL-PNpu0kEMuEojnGc3Me8QOQgzE2CeEUwRov2VEoVQD2DUghF436h1boWplI5RZH7AVSMAGtZCH7CjnewDoDMAHdihxrY0wZsXshZuJx4GXu1Sr5-98nOclxHJHyW0f-F9Kecl8jhP5ZXKJF5duqVDPX4gx8ETBTdzTVA8XPCWefX1KY8wn7P3gpkwfn-9jdnP-8_fZZXP96-Lq7Md142WrSiM9tpoUtoY0ad_uxhFio4HEhkg54XTfu7bf9AYHbxxq1SF166HrYRCtl8fs677uNsU_C-Vi5zHvOnKB4pKtEEYimM7Iin55hd7HJdUJnighUYLQlfr8TC2bmXq7TePs0oN9WV0FxB7wKeacaPiHINhdPnafj6352Kd8rKqSeSX5sbgyxlCSG6e3VblXc_0n3FL63_Yb1iN7hqRR
CitedBy_id	crossref_primary_10_1186_s12957_020_01933_5 crossref_primary_10_1007_s12325_021_01737_3
Cites_doi	10.1093/annonc/mdy424.037 10.1016/j.eururo.2010.09.034 10.1038/nm.3541 10.1007/s00345-008-0368-7 10.1200/JCO.2012.47.4940 10.1200/JCO.2016.70.7398 10.1016/S1470-2045(16)30107-3 10.1038/nri2506 10.1038/ncomms12624 10.1056/NEJMoa1805453 10.1038/nature10169 10.1200/JCO.2018.36.15_suppl.4500 10.1371/journal.pone.0007669 10.1093/annonc/mdw328 10.1007/s11255-017-1703-y 10.1126/science.1846706 10.1158/1078-0432.CCR-06-1870 10.1158/1078-0432.CCR-06-0818 10.1200/JCO.2017.73.5324 10.1200/JCO.2018.36.6_suppl.578 10.1093/annonc/mdy454 10.1056/NEJMoa1611406 10.1586/era.09.43 10.1056/NEJMoa1816714 10.1056/NEJMoa1803675 10.1016/j.clgc.2013.10.001 10.1016/j.eururo.2013.08.012 10.1016/S1470-2045(13)70093-7 10.1016/S0140-6736(01)06103-7 10.2174/1566524043359674 10.1084/jem.20140559 10.1158/2326-6066.CIR-14-0053 10.1152/physrev.00038.2010 10.1002/cncr.24230 10.1016/S0140-6736(16)00559-6 10.1056/NEJMoa003013 10.1016/S1470-2045(12)70559-4 10.1038/nm1096-1096 10.3109/02841860903521111 10.1056/NEJMoa1303989 10.1016/S0140-6736(11)61613-9 10.1093/annonc/mdv149 10.1053/j.seminoncol.2013.05.008 10.4049/jimmunol.160.3.1224 10.1056/NEJMoa1712126 10.1056/NEJMoa1816047 10.1056/NEJMoa1510665 10.1158/1078-0432.CCR-07-4921 10.1016/S1470-2045(15)00290-9
ContentType	Journal Article
Copyright	Springer Nature B.V. 2019 International Urology and Nephrology is a copyright of Springer, (2019). All Rights Reserved.
Copyright_xml	– notice: Springer Nature B.V. 2019 – notice: International Urology and Nephrology is a copyright of Springer, (2019). All Rights Reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8
DOI	10.1007/s11255-019-02264-5
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1573-2584
EndPage	2117
ExternalDocumentID	31468288 10_1007_s11255_019_02264_5
Genre	Comparative Study Review Journal Article Case Reports
GroupedDBID	--- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 2.D 203 28- 29J 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAK LLZTM M1P M4Y MA- N2Q NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7QP 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c375t-3c176e5178e6e6c7226422b60e2bee5a2a6dda7dbd81fc8a16591e94f9d0f27c3
IEDL.DBID	7X7
ISICitedReferencesCount	2
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000495786500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0301-1623 1573-2584
IngestDate	Fri Sep 05 08:21:50 EDT 2025 Tue Nov 04 23:41:40 EST 2025 Wed Feb 19 02:31:07 EST 2025 Sat Nov 29 02:39:55 EST 2025 Tue Nov 18 21:55:07 EST 2025 Fri Feb 21 02:35:42 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	12
Keywords	Metastatic renal cell carcinoma Immunotherapy Tyrosine kinase inhibitors
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c375t-3c176e5178e6e6c7226422b60e2bee5a2a6dda7dbd81fc8a16591e94f9d0f27c3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Case Study-2 ObjectType-Review-5 ObjectType-Feature-3 content type line 23 ObjectType-Article-4 ObjectType-Report-1
ORCID	0000-0001-8628-0864
PMID	31468288
PQID	2282313026
PQPubID	33540
PageCount	11
ParticipantIDs	proquest_miscellaneous_2283108983 proquest_journals_2282313026 pubmed_primary_31468288 crossref_primary_10_1007_s11255_019_02264_5 crossref_citationtrail_10_1007_s11255_019_02264_5 springer_journals_10_1007_s11255_019_02264_5
PublicationCentury	2000
PublicationDate	20191200 2019-12-00 2019-Dec 20191201
PublicationDateYYYYMMDD	2019-12-01
PublicationDate_xml	– month: 12 year: 2019 text: 20191200
PublicationDecade	2010
PublicationPlace	Dordrecht
PublicationPlace_xml	– name: Dordrecht – name: Netherlands
PublicationTitle	International urology and nephrology
PublicationTitleAbbrev	Int Urol Nephrol
PublicationTitleAlternate	Int Urol Nephrol
PublicationYear	2019
Publisher	Springer Netherlands Springer Nature B.V
Publisher_xml	– name: Springer Netherlands – name: Springer Nature B.V
References	Motzer, Hutson, Cella, Reeves, Hawkins, Guo (CR18) 2013; 369 Gabrilovich, Chen, Girgis, Cunningham, Meny, Nadaf (CR23) 1996; 2 Bex, Mulders, Jewett, Wagstaff, van Thienen, Blank (CR16) 2018; 5 Motzer, Nosov, Eisen, Bondarenko, Lesovoy, Lipatov (CR19) 2013; 31 Bottaro, Rubin, Faletto, Chan, Kmiecik, Vande Woude (CR47) 1991; 251 Wallin, Bendell, Funke, Sznol, Korski, Jones (CR28) 2016; 30 Motzer, Powles, Atkins, Escudier, McDermott, Suarez (CR33) 2018; 36 Linehan, Pinto, Srinivasan, Merino, Choyke, Choyke (CR1) 2007; 13 Abel, Culp, Tannir, Matin, Tamboli, Jonasch (CR5) 2011; 59 Haas, Manola, Uzzo, Flaherty, Wood, Kane (CR8) 2016; 387 Méjean, Ravaud, Thezenas, Colas, Beauval, Bensalah (CR15) 2018; 379 Bex, Van der Veldt, Blank, Meijerink, Boven, Haanen (CR7) 2010; 49 Choueiri, Escudier, Powles, Tannir, Mainwaring, Rini (CR37) 2016; 17 Peruzzi, Bottaro (CR49) 2006; 12 Rini, Escudier, Tomczak, Kaprin, Szczylik, Hutson (CR40) 2011; 378 Goel, Duda, Xu, Munn, Boucher, Fukumura (CR25) 2011; 91 Seastone, Elson, Garcia, Chao, Suh, Angelov (CR43) 2014; 12 Escudier, Porta, Schmidinger, Rioux-Leclercq, Bex, Khoo (CR12) 2016; 27 Mickisch, Garin, van Poppel, de Prijck, Sylvester (CR14) 2001; 358 Flanigan, Salmon, Blumenstein, Bearman, Roy, McGrath (CR13) 2001; 345 Gross-Goupil, Kwon, Eto, Ye, Miyake, Seo (CR10) 2018; 29 Facciabene, Peng, Hagemann, Balint, Barchetti, Wang (CR31) 2011; 475 Marchioni, Bandini, Pompe, Tian, Martel, Kapoor (CR45) 2017; 49 Motzer, Escudier, Tomczak, Hutson, Michaelson, Negrier (CR41) 2013; 14 Choueiri, Halabi, Sanford, Hahn, Michaelson, Walsh (CR20) 2017; 35 Motzer, Penkov, Haanen, Rini, Albiges, Campbell (CR34) 2019; 380 Dharmawardana, Giubellino, Bottaro (CR48) 2004; 4 McDermott, Lee, Szczylik, Donskov, Malik, Alekseev (CR22) 2018; 36S Oyama, Ran, Ishida, Nadaf, Kerr, Carbone (CR24) 1998; 160 Hodi, Lawrence, Lezcano, Wu, Zhou, Sasada (CR27) 2014; 2 Gabrilovich, Nagaraj (CR29) 2009; 9 Linehan, Pinto, Bratslavsky, Pfaffenroth, Merino, Vocke (CR2) 2009; 115 Bex, van der Veldt, Blank, van den Eertwegh, Boven, Horenblas (CR6) 2009; 27 Rini, Huseni, Atkins, McDermott, Powles, Escudier (CR36) 2018 Motzer, Hutson, Glen, Michaelson, Molina, Eisen (CR39) 2015; 16 Roland, Lynn, Toombs, Dineen, Udugamasooriya, Brekken (CR30) 2009; 4 Tawbi, Forsyth, Algazi, Hamid, Hodi, Moschos (CR44) 2018; 379 Motzer, Tannir, McDermott, Arén Frontera, Melichar, Choueiri (CR21) 2018; 378 McDermott, Atkins (CR4) 2013; 40 Ravaud, Motzer, Pandha, George, Pantuck, Patel (CR9) 2016; 375 Motzer, Haas, Donskov, Gross-Goupil, Varlamov, Kopyltsov (CR11) 2017; 35 Rini, Plimack, Stus, Gafanov, Hawkins, Nosov (CR35) 2019; 380 McKay, Kroeger, Xie, Lee, Knox, Bjarnason (CR38) 2014; 65 Giubellino, Linehan, Bottaro (CR50) 2009; 9 Voron, Colussi, Marcheteau, Pernot, Nizard, Pointet (CR32) 2015; 212 Motz, Santoro, Wang, Garrabrant, Lastra, Hagemann (CR26) 2014; 201420 Nickerson, Jaeger, Shi, Durocher, Mahurkar, Zaridze (CR3) 2008; 14 Motzer, Escudier, McDermott, George, Hammers, Srinivas (CR42) 2015; 373 Heng, Xie, Regan, Harshman, Bjarnason, Vaishampayan (CR17) 2013; 14 Ravaud, Oudard, De Fromont, Chevreau, Gravis, Zanetta (CR46) 2015; 26 WM Linehan (2264_CR2) 2009; 115 S Goel (2264_CR25) 2011; 91 DY Heng (2264_CR17) 2013; 14 R Motzer (2264_CR33) 2018; 36 A Giubellino (2264_CR50) 2009; 9 JJ Wallin (2264_CR28) 2016; 30 A Ravaud (2264_CR9) 2016; 375 A Méjean (2264_CR15) 2018; 379 DF McDermott (2264_CR22) 2018; 36S BI Rini (2264_CR35) 2019; 380 B Escudier (2264_CR12) 2016; 27 HA Tawbi (2264_CR44) 2018; 379 T Voron (2264_CR32) 2015; 212 DI Gabrilovich (2264_CR29) 2009; 9 FS Hodi (2264_CR27) 2014; 2 T Oyama (2264_CR24) 1998; 160 RJ Motzer (2264_CR41) 2013; 14 RJ Motzer (2264_CR34) 2019; 380 RJ Motzer (2264_CR42) 2015; 373 ML Nickerson (2264_CR3) 2008; 14 A Bex (2264_CR16) 2018; 5 RJ Motzer (2264_CR18) 2013; 369 A Bex (2264_CR7) 2010; 49 A Bex (2264_CR6) 2009; 27 TK Choueiri (2264_CR20) 2017; 35 RJ Motzer (2264_CR21) 2018; 378 BI Rini (2264_CR40) 2011; 378 M Marchioni (2264_CR45) 2017; 49 B Peruzzi (2264_CR49) 2006; 12 A Facciabene (2264_CR31) 2011; 475 DI Gabrilovich (2264_CR23) 1996; 2 BI Rini (2264_CR36) 2018 RR McKay (2264_CR38) 2014; 65 GT Motz (2264_CR26) 2014; 201420 RC Flanigan (2264_CR13) 2001; 345 NB Haas (2264_CR8) 2016; 387 GH Mickisch (2264_CR14) 2001; 358 TK Choueiri (2264_CR37) 2016; 17 RJ Motzer (2264_CR19) 2013; 31 CL Roland (2264_CR30) 2009; 4 PG Dharmawardana (2264_CR48) 2004; 4 RJ Motzer (2264_CR39) 2015; 16 DF McDermott (2264_CR4) 2013; 40 RJ Motzer (2264_CR11) 2017; 35 EJ Abel (2264_CR5) 2011; 59 A Ravaud (2264_CR46) 2015; 26 WM Linehan (2264_CR1) 2007; 13 DJ Seastone (2264_CR43) 2014; 12 DP Bottaro (2264_CR47) 1991; 251 M Gross-Goupil (2264_CR10) 2018; 29
References_xml	– volume: 40 start-page: 492 issue: 4 year: 2013 end-page: 498 ident: CR4 article-title: Immune therapy for kidney cancer: a second dawn? publication-title: Semin Oncol – volume: 5 start-page: 167 year: 2018 end-page: 170 ident: CR16 article-title: Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial publication-title: JAMA Oncol – volume: 49 start-page: 2143 issue: 12 year: 2017 end-page: 2149 ident: CR45 article-title: Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era publication-title: Int Urol Nephrol – volume: 17 start-page: 917 year: 2016 end-page: 927 ident: CR37 article-title: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial publication-title: Lancet Oncol – volume: 251 start-page: 802 year: 1991 end-page: 804 ident: CR47 article-title: Identification of the hepatocyte growth factor receptor as the c- proto-oncogene product publication-title: Science – volume: 475 start-page: 226 issue: 7355 year: 2011 end-page: 230 ident: CR31 article-title: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells publication-title: Nature – volume: 14 start-page: 552 year: 2013 end-page: 562 ident: CR41 article-title: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial publication-title: Lancet Oncol – volume: 380 start-page: 1116 issue: 12 year: 2019 end-page: 1127 ident: CR35 article-title: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma publication-title: N Engl J Med – volume: 12 start-page: 111 issue: 2 year: 2014 end-page: 116 ident: CR43 article-title: Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma publication-title: Clin Genitourin Cancer – volume: 201420 start-page: 607 issue: 6 year: 2014 end-page: 615 ident: CR26 article-title: Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors publication-title: Nat Med – volume: 378 start-page: 1931 year: 2011 end-page: 1939 ident: CR40 article-title: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial publication-title: Lancet – volume: 212 start-page: 139 issue: 2 year: 2015 end-page: 148 ident: CR32 article-title: VEGF-A modulates expression of inhibitory checkpoints on CD8 + T cells in tumors publication-title: J Exp Med – volume: 380 start-page: 1103 issue: 12 year: 2019 end-page: 1115 ident: CR34 article-title: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma publication-title: N Engl J Med – volume: 27 start-page: v58 issue: suppl 5 year: 2016 end-page: v68 ident: CR12 article-title: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 379 start-page: 417 issue: 5 year: 2018 end-page: 427 ident: CR15 article-title: Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma publication-title: N Engl J Med – volume: 65 start-page: 577 issue: 3 year: 2014 end-page: 584 ident: CR38 article-title: Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy publication-title: Eur Urol – volume: 12 start-page: 3657 year: 2006 end-page: 3660 ident: CR49 article-title: Targeting the c-Met signaling pathway in cancer publication-title: Clin Cancer Res – volume: 369 start-page: 722 issue: 8 year: 2013 end-page: 731 ident: CR18 article-title: Pazopanib versus sunitinib in metastatic renal-cell carcinoma publication-title: N Engl J Med – volume: 9 start-page: 785 year: 2009 end-page: 793 ident: CR50 article-title: Targeting the Met signaling pathway in renal cancer publication-title: Expert Rev Anticancer Ther – volume: 387 start-page: 2008 issue: 10032 year: 2016 end-page: 2016 ident: CR8 article-title: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial publication-title: Lancet – volume: 4 start-page: e7669 issue: 11 year: 2009 ident: CR30 article-title: Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer publication-title: PLoS One – volume: 27 start-page: 533 issue: 4 year: 2009 end-page: 539 ident: CR6 article-title: Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery publication-title: World J Urol – volume: 35 start-page: 3916 issue: 35 year: 2017 end-page: 3923 ident: CR11 article-title: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma publication-title: J Clin Oncol – volume: 378 start-page: 1277 issue: 14 year: 2018 end-page: 1290 ident: CR21 article-title: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma publication-title: N Engl J Med – volume: 49 start-page: 520 issue: 4 year: 2010 end-page: 523 ident: CR7 article-title: Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib publication-title: Acta Oncol – volume: 13 start-page: 671 year: 2007 end-page: 679 ident: CR1 article-title: Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics publication-title: Clin Cancer Res – volume: 14 start-page: 141 issue: 2 year: 2013 end-page: 148 ident: CR17 article-title: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study publication-title: Lancet Oncol – volume: 14 start-page: 4726 issue: 15 year: 2008 end-page: 4734 ident: CR3 article-title: Improved identification of Von Hippel-Lindau gene alterations in clear cell renal tumors publication-title: Clin Cancer Res – volume: 2 start-page: 632 issue: 7 year: 2014 end-page: 642 ident: CR27 article-title: Bevacizumab plus ipilimumab in patients with metastatic melanoma publication-title: Cancer Immunol Res – volume: 59 start-page: 10 issue: 1 year: 2011 end-page: 15 ident: CR5 article-title: Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma publication-title: Eur Urol – volume: 115 start-page: 2252 year: 2009 end-page: 2261 ident: CR2 article-title: Hereditary kidney cancer: unique opportunity for disease-based therapy publication-title: Cancer – volume: 9 start-page: 162 issue: 3 year: 2009 end-page: 174 ident: CR29 article-title: Myeloid-derived suppressor cells as regulators of the immune system publication-title: Nat Rev Immunol – volume: 375 start-page: 2246 issue: 23 year: 2016 end-page: 2254 ident: CR9 article-title: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy publication-title: N Engl J Med – volume: 26 start-page: 1123 year: 2015 end-page: 1128 ident: CR46 article-title: First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)† publication-title: Ann Oncol – volume: 29 start-page: 2371 issue: 12 year: 2018 end-page: 2378 ident: CR10 article-title: Axitinib versus placebo as an adjuvant treatment for renal cell carcinoma: results from the phase III. Randomized ATLAS Trial publication-title: Ann Oncol – volume: 35 start-page: 591 issue: 6 year: 2017 end-page: 597 ident: CR20 article-title: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial publication-title: J Clin Oncol – volume: 379 start-page: 722 issue: 8 year: 2018 end-page: 730 ident: CR44 article-title: Combined nivolumab and ipilimumab in melanoma metastatic to the brain publication-title: N Engl J Med – volume: 4 start-page: 855 year: 2004 end-page: 868 ident: CR48 article-title: Hereditary papillary renal carcinoma type I publication-title: Curr Mol Med – volume: 31 start-page: 3791 issue: 30 year: 2013 end-page: 3799 ident: CR19 article-title: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma:results from a phase III trial publication-title: J Clin Oncol – volume: 2 start-page: 1096 issue: 10 year: 1996 end-page: 1103 ident: CR23 article-title: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells publication-title: Nat Med – volume: 36 start-page: 578 year: 2018 ident: CR33 article-title: IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma publication-title: J Clin Oncol – volume: 373 start-page: 1803 issue: 19 year: 2015 end-page: 1813 ident: CR42 article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma publication-title: N Engl J Med – volume: 36S start-page: ASCO#4500 year: 2018 ident: CR22 article-title: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427 publication-title: J Clin Oncol – volume: 358 start-page: 966 issue: 9286 year: 2001 end-page: 970 ident: CR14 article-title: European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal- cell carcinoma: a randomised trial publication-title: Lancet – volume: 160 start-page: 1224 issue: 3 year: 1998 end-page: 1232 ident: CR24 article-title: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells publication-title: J Immunol – volume: 30 start-page: 12624 issue: 7 year: 2016 ident: CR28 article-title: Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma publication-title: Nat Commun – volume: 16 start-page: 1473 issue: 15 year: 2015 end-page: 1482 ident: CR39 article-title: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial publication-title: Lancet Oncol – volume: 91 start-page: 1071 issue: 3 year: 2011 end-page: 1121 ident: CR25 article-title: Normalization of the vasculature for treatment of cancer and other diseases publication-title: Physiol Rev – year: 2018 ident: CR36 article-title: Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) publication-title: Ann Oncol doi: 10.1093/annonc/mdy424.037 – volume: 345 start-page: 1655 issue: 23 year: 2001 end-page: 1659 ident: CR13 article-title: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer publication-title: N Engl J Med – volume: 59 start-page: 10 issue: 1 year: 2011 ident: 2264_CR5 publication-title: Eur Urol doi: 10.1016/j.eururo.2010.09.034 – volume: 201420 start-page: 607 issue: 6 year: 2014 ident: 2264_CR26 publication-title: Nat Med doi: 10.1038/nm.3541 – volume: 27 start-page: 533 issue: 4 year: 2009 ident: 2264_CR6 publication-title: World J Urol doi: 10.1007/s00345-008-0368-7 – volume: 31 start-page: 3791 issue: 30 year: 2013 ident: 2264_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.47.4940 – volume: 35 start-page: 591 issue: 6 year: 2017 ident: 2264_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.70.7398 – volume: 17 start-page: 917 year: 2016 ident: 2264_CR37 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30107-3 – volume: 9 start-page: 162 issue: 3 year: 2009 ident: 2264_CR29 publication-title: Nat Rev Immunol doi: 10.1038/nri2506 – year: 2018 ident: 2264_CR36 publication-title: Ann Oncol doi: 10.1093/annonc/mdy424.037 – volume: 30 start-page: 12624 issue: 7 year: 2016 ident: 2264_CR28 publication-title: Nat Commun doi: 10.1038/ncomms12624 – volume: 379 start-page: 722 issue: 8 year: 2018 ident: 2264_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa1805453 – volume: 475 start-page: 226 issue: 7355 year: 2011 ident: 2264_CR31 publication-title: Nature doi: 10.1038/nature10169 – volume: 36S start-page: ASCO#4500 year: 2018 ident: 2264_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.4500 – volume: 4 start-page: e7669 issue: 11 year: 2009 ident: 2264_CR30 publication-title: PLoS One doi: 10.1371/journal.pone.0007669 – volume: 27 start-page: v58 issue: suppl 5 year: 2016 ident: 2264_CR12 publication-title: Ann Oncol doi: 10.1093/annonc/mdw328 – volume: 49 start-page: 2143 issue: 12 year: 2017 ident: 2264_CR45 publication-title: Int Urol Nephrol doi: 10.1007/s11255-017-1703-y – volume: 251 start-page: 802 year: 1991 ident: 2264_CR47 publication-title: Science doi: 10.1126/science.1846706 – volume: 13 start-page: 671 year: 2007 ident: 2264_CR1 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1870 – volume: 12 start-page: 3657 year: 2006 ident: 2264_CR49 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0818 – volume: 35 start-page: 3916 issue: 35 year: 2017 ident: 2264_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.5324 – volume: 36 start-page: 578 year: 2018 ident: 2264_CR33 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.6_suppl.578 – volume: 5 start-page: 167 year: 2018 ident: 2264_CR16 publication-title: JAMA Oncol – volume: 29 start-page: 2371 issue: 12 year: 2018 ident: 2264_CR10 publication-title: Ann Oncol doi: 10.1093/annonc/mdy454 – volume: 375 start-page: 2246 issue: 23 year: 2016 ident: 2264_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa1611406 – volume: 9 start-page: 785 year: 2009 ident: 2264_CR50 publication-title: Expert Rev Anticancer Ther doi: 10.1586/era.09.43 – volume: 380 start-page: 1116 issue: 12 year: 2019 ident: 2264_CR35 publication-title: N Engl J Med doi: 10.1056/NEJMoa1816714 – volume: 379 start-page: 417 issue: 5 year: 2018 ident: 2264_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1803675 – volume: 12 start-page: 111 issue: 2 year: 2014 ident: 2264_CR43 publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2013.10.001 – volume: 65 start-page: 577 issue: 3 year: 2014 ident: 2264_CR38 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.012 – volume: 14 start-page: 552 year: 2013 ident: 2264_CR41 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70093-7 – volume: 358 start-page: 966 issue: 9286 year: 2001 ident: 2264_CR14 publication-title: Lancet doi: 10.1016/S0140-6736(01)06103-7 – volume: 4 start-page: 855 year: 2004 ident: 2264_CR48 publication-title: Curr Mol Med doi: 10.2174/1566524043359674 – volume: 212 start-page: 139 issue: 2 year: 2015 ident: 2264_CR32 publication-title: J Exp Med doi: 10.1084/jem.20140559 – volume: 2 start-page: 632 issue: 7 year: 2014 ident: 2264_CR27 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0053 – volume: 91 start-page: 1071 issue: 3 year: 2011 ident: 2264_CR25 publication-title: Physiol Rev doi: 10.1152/physrev.00038.2010 – volume: 115 start-page: 2252 year: 2009 ident: 2264_CR2 publication-title: Cancer doi: 10.1002/cncr.24230 – volume: 387 start-page: 2008 issue: 10032 year: 2016 ident: 2264_CR8 publication-title: Lancet doi: 10.1016/S0140-6736(16)00559-6 – volume: 345 start-page: 1655 issue: 23 year: 2001 ident: 2264_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa003013 – volume: 14 start-page: 141 issue: 2 year: 2013 ident: 2264_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70559-4 – volume: 2 start-page: 1096 issue: 10 year: 1996 ident: 2264_CR23 publication-title: Nat Med doi: 10.1038/nm1096-1096 – volume: 49 start-page: 520 issue: 4 year: 2010 ident: 2264_CR7 publication-title: Acta Oncol doi: 10.3109/02841860903521111 – volume: 369 start-page: 722 issue: 8 year: 2013 ident: 2264_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa1303989 – volume: 378 start-page: 1931 year: 2011 ident: 2264_CR40 publication-title: Lancet doi: 10.1016/S0140-6736(11)61613-9 – volume: 26 start-page: 1123 year: 2015 ident: 2264_CR46 publication-title: Ann Oncol doi: 10.1093/annonc/mdv149 – volume: 40 start-page: 492 issue: 4 year: 2013 ident: 2264_CR4 publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2013.05.008 – volume: 160 start-page: 1224 issue: 3 year: 1998 ident: 2264_CR24 publication-title: J Immunol doi: 10.4049/jimmunol.160.3.1224 – volume: 378 start-page: 1277 issue: 14 year: 2018 ident: 2264_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa1712126 – volume: 380 start-page: 1103 issue: 12 year: 2019 ident: 2264_CR34 publication-title: N Engl J Med doi: 10.1056/NEJMoa1816047 – volume: 373 start-page: 1803 issue: 19 year: 2015 ident: 2264_CR42 publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 – volume: 14 start-page: 4726 issue: 15 year: 2008 ident: 2264_CR3 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4921 – volume: 16 start-page: 1473 issue: 15 year: 2015 ident: 2264_CR39 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00290-9
SSID	ssj0009800
Score	2.2158558
SecondaryResourceType	review_article
Snippet	Objectives Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which... Treatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment option is... ObjectivesTreatment for advanced renal cell carcinoma (RCC) has become increasingly more complex over the last several years. Objective 1 is to which treatment...
SourceID	proquest pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	2107
SubjectTerms	Aged Carcinoma, Renal Cell - therapy Clear cell-type renal cell carcinoma Clinical trials Clinical Trials as Topic Decision making Drug development Female Humans Immune checkpoint inhibitors Immunotherapy Kidney cancer Kidney Neoplasms - therapy Male Medicine Medicine & Public Health Metastases Metastasis Middle Aged Molecular Targeted Therapy Monoclonal antibodies Nephrology Patients Risk groups Targeted cancer therapy Tyrosine Urology Urology - Review Vascular endothelial growth factor
SummonAdditionalLinks	– databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB9aW4ovWm21W22J4JsGNtmPJL6VUu1Lpdgqvi3ZZAIH3p3c3hX875vZjzvEKtTnnU1mZyaZZGd-MwCHUmHhjBJc2tLyPLc114gFL1xwaAK5sLRtNqHOz_X1tfnZg8KaIdt9CEm2O_UK7BZ9MSWaGZ4S-pMXL-FVdHeaGjZc_LpaldrVHfAkmi4X0bv3UJl_j3HfHT04Yz6Ij7Zu53TzeQy_hY3-mMm-dHaxBS9wsg1vfvSB9HdQndkxsmlg1CYh7nYnbERAkR6OdccoWWPRsPHQPJd1GePo2UAxmrAZ0hz06585Mp4Zo9JQ8fI9bd7D5em331-_877XAneZKuY8c0KVWAilscTSKWJYyrpMUdZRdzaq0nurfO21CE5bURZGoMmD8WmQymU7sDaJ_H4AVlrhfVrnJeYhjxe66P9CXvvaYMiswzQBMYi8cn0hcuqHcVOtSiiT5KoouaqVXFUkcLR857Yrw_Ek9f6gyapfkk0lJUU8s3jnTOBg-TguJhKTneB00dLE4642Oktgt7OA5XQZgdTi1yRwPKh7NfjjvHz8P_I9WJdkMW3CzD6szWcL_ASv3Z_5qJl9bg39LxU-9rg priority: 102 providerName: Springer Nature
Title	Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios
URI	https://link.springer.com/article/10.1007/s11255-019-02264-5 https://www.ncbi.nlm.nih.gov/pubmed/31468288 https://www.proquest.com/docview/2282313026 https://www.proquest.com/docview/2283108983
Volume	51
WOSCitedRecordID	wos000495786500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAVX databaseName: Springer Nature - Connect here FIRST to enable access customDbUrl: eissn: 1573-2584 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009800 issn: 0301-1623 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAXyqsQWiojcQOL2HnY5oIoauHCqioP7S1y7LG0Et0tm10k_j2exNkVquill0hRnNjxfPbYnscH8EoqrJxRgktbW16WtuUaseKVCw5NIBWW92QTajLR06k5SwduXXKrHOfEfqL2C0dn5G-lJINVEbcM7y9_cWKNIutqotC4DbtEm004V1O1TbqrhxCUCGIuop5PQTND6FzU7OS2ZnhOsaS8-lcxXVltXrGU9grodO-mTX8A99PSk30YsPIQbuH8Edz9kozrj6H5ZC-QLQIj6oQ4A75jMwoeSSFafxg5cKw7djES6rLBixw9G0vM5myJVAeZA5gjQC0ZpYuKG_JF9wS-n558-_iZJ_4F7gpVrXjhhKqxEkpjjbVT1E9StnWOso3ytFG83lvlW69FcNqKujICTRmMz4NUrtiHnXls7zNgtRXe521ZYxnKuMmLOjGUrW8NhsI6zDMQY-c3LiUnJ46Mn802rTIJrIkCa3qBNVUGrzfvXA6pOa4tfTgKp0nDtGu2ksng5eZxHGDUTXaOi3VfJi6BtdFFBk8HLGyqKyhwLf5NBm9GcGw__v-2PL--LQdwTxIwe6eZQ9hZLdf4Au6436tZtzzqId5f9RHsHp9Mzs7j3fnXH38BDioEMw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgqCX8qYpBYwEJ7BInIdjJIQQUFq1XXEo0t5cxx5LK9HdkuyC-qf4jXjy2BWq6K0HznHsif3Nw5kXwAshMbdKJlyYwvAsMxUvEXOeW29ReVJhcdtsQo5G5Xisvq7B7yEXhsIqB5nYCmo3s_SP_I0Q5LBKw5Xh_dkPTl2jyLs6tNDoYHGA57_Cla15t_8pnO9LIXY_H3_c431XAW5Tmc95ahNZYJ7IEgssrKRMUiGqIkZRBSpNINo5I13lysTb0iRFrhJUmVcu9kLaNMx7Da4HOS7psifHclXkt-xSXgLT8CTYFX2STpeqFywJCpNTPKYVef63Irxg3V7wzLYKb_f2_7ZVd2CzN63Zh44X7sIaTu_BzaM-eOA-6C_mFNnMM2oNEST8Wzah5Jg-Be2cUYDKomGnQ8Ng1kXJo2PDiMmU1UhrkLuDWWKYmlE5LFNPZs0D-HYln_cQ1qeB3i1ghUmci6uswMxn4RIbdL7PKlcp9KmxGEeQDIetbV98nXqAfNerstEEEB0AoluA6DyCV8t3zrrSI5eO3hnAoHsx1OgVEiJ4vnwcBAhtk5nibNGOCSZ-qco0gkcd9pbLpZSYF74mgtcDGFeT_5uW7ctpeQa39o6PDvXh_ujgMWwIYoo2QGgH1uf1Ap_ADftzPmnqpy17MTi5apD-AXdUXnU
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLaq48IYGChgJTmA1cR5OkBAC2oWqsFohkHoLjj2WVmp3y2YX1L_Gr2Mmj12hit564BzHHjvfjMfxfDMAz5TG1BY6kspkRiaJqWSOmMrUeouF5y0sbIpN6NEoPzoqxhvwu-fCcFhlbxMbQ-1mlv-R7yrFF1YxHRl2fRcWMd4bvjn9IbmCFN-09uU0Wogc4tkvOr7Vrw_26Fs_V2q4__X9R9lVGJA21ulCxjbSGaaRzjHDzGpmlSpVZSGqiiQ2NAHnjHaVyyNvcxNlaRFhkfjChV5pG1O_V2BTk5ORDGDz3f5o_GWd8jdvCTCkQjIiL6Oj7LTEPfIrOGiukCGPKdO_t8Vzvu65e9pm-xve-J8X7iZc75xu8bbVkluwgdPbsPW5Cyu4A-UHc4Ji5gUXjSDb_0pMmDbTkdPOBIeuLGtx0pcSFm38PDrRt5hMxRx5DL4IEZZVaS44UZaZT2b1Xfh2KdO7B4MpybsNIjORc2GVZJj4hI635A34pHJVgT42FsMAov7Dl7ZLy87VQY7LdUJpBktJYCkbsJRpAC9W75y2SUkubL3TA6PsDFRdrlERwNPVYzItvExmirNl04ac_7zI4wDutzhcDRczZY9mE8DLHpjrzv8ty4OLZXkCW4TN8tPB6PAhXFOsH03k0A4MFvMlPoKr9udiUs8fd7om4Ptlo_QP_eVolQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Game+of+thrones%3A+immunotherapy+versus+molecular+targeted+therapy+in+renal+cell+cancer+scenarios&rft.jtitle=International+urology+and+nephrology&rft.au=Cetin%2C+Bulent&rft.au=Kosar%2C+Alim&rft.date=2019-12-01&rft.pub=Springer+Nature+B.V&rft.issn=0301-1623&rft.eissn=1573-2584&rft.volume=51&rft.issue=12&rft.spage=2107&rft.epage=2117&rft_id=info:doi/10.1007%2Fs11255-019-02264-5&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0301-1623&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0301-1623&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0301-1623&client=summon